4.2 Article

Primary and secondary surveys on epidemiology of Sjogren's syndrome in Japan

Journal

MODERN RHEUMATOLOGY
Volume 24, Issue 3, Pages 464-470

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.3109/14397595.2013.843765

Keywords

Criteria; Epidemiology; Extra-glandular form; Glandular form; Sjogren's syndrome; Treatment

Categories

Funding

  1. Ministry of Health, Labour and Welfare of Japan
  2. Grants-in-Aid for Scientific Research [24592783] Funding Source: KAKEN

Ask authors/readers for more resources

Objective. To characterize the epidemiology of Sjogren's syndrome (SS), including prevalence, disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets, and treatment used in Japan. Methods. The Research Team for Autoimmune Diseases, the Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare conducted primary and secondary surveys on epidemiology of SS in 2011. The primary survey covered 4,729 out of 14,095 Japan-wide Hospital Departments to investigate the prevalence of SS. The secondary survey encompassed 214 Hospital Departments that agreed to the survey, to characterize disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets, and treatments. Results. The number of patients with SS in Japan estimated by the primary survey was 68,483. The secondary survey involving data collected from 2,195 SS patients from 98 Hospital Departments showed that the mean age of patients was 60.8 +/- 15.2 years, male/female ratio was 1/17.4, primary/secondary SS was about 60%/40% and glandular/extra-glandular form in primary SS was about 70%/25%. The satisfaction rate was 53.8% for the 1999 revised Japanese Ministry of Health criteria for the diagnosis of SS, 47.7% for the 2002 American-European Consensus Group classification criteria for SS and 49.6% for 2012 American College of Rheumatology classification criteria for SS. Corticosteroids were used by 752 of 2,195 patients (34%), immunosuppressants by 358 patients (16%), biologics by 68 patients (3%) and secretagogues by 695 patients (32%). Conclusion. The surveys provided valuable information on the epidemiology of SS including prevalence, disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets and treatments used today in Japan.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication

Hiromu Ito, Keiichiro Nishida, Toshihisa Kojima, Isao Matsushita, Masayo Kojima, Shintaro Hirata, Yuko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masaaki Mori, Akio Morinobu, Atsuko Murashima, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Takeo Nakayama, Hisashi Yamanaka, Yutaka Kawahito, Masayoshi Harigai

Summary: This study aimed to update the clinical practice guidelines for the management of rheumatoid arthritis (RA) in Japan and develop an algorithm for non-drug and surgical treatments. The guidelines were updated using the Grading of Recommendations, Assessment, Development, and Evaluation method, and recommendations were developed based on 19 clinical questions regarding non-drug and surgical treatments. The study also created an original algorithm for the treatment of RA.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication

Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Hiromu Ito, Toshihisa Kojima, Isao Matsushita, Keiichiro Nishida, Masaaki Mori, Atsuko Murashima, Hisashi Yamanaka, Takeo Nakayama, Masayo Kojima, Masayoshi Harigai

Summary: The Japan College of Rheumatology has updated the clinical practice guidelines for rheumatoid arthritis, providing a useful tool for rheumatologists, healthcare professionals, and patients to make shared decisions in various clinical situations.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B. McInnes, Naveed Sattar, Tanja A. Stamm, Tsutomu Takeuchi, Michael Trauner, Desiree van der Heijde, Marieke Voshaar, Kevin L. Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Ruediger R. Burmester, Johannes W. J. Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H. Choy, Catalin Codreanu, Bernard Combe, Mary K. Crow, Maarten de Wit, Paul Emery, Roy M. Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L. Hyrich, Annamaria Iagnocco, John D. Isaacs, Joel M. Kremer, Xavier Mariette, Peter Merkel, Eduardo F. Mysler, Peter Nash, Michael T. Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S. Smolen

Summary: This paper is an updated consensus document on the medical use of IL-6 pathway inhibition in the treatment of inflammatory diseases. The document provides comprehensive consensus statements based on systematic literature research and expert opinion, covering various aspects of IL-6 pathway inhibitors, including dosing, indications, and clinical considerations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)

Yoshiya Tanaka, Masafumi Kawanishi, Megumi Nakanishi, Hironori Yamasaki, Tsutomu Takeuchi

Summary: Subcutaneous ozoralizumab treatment for 52 weeks demonstrated significant therapeutic effects and acceptable tolerability in patients with active rheumatoid arthritis.

MODERN RHEUMATOLOGY (2023)

Review Rheumatology

Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe

Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial

Tsutomu Takeuchi, Sakae Tanaka, Mitsuru Murata, Yoshiya Tanaka

Summary: This study aimed to evaluate the efficacy and safety of TAS5315 in Japanese patients with refractory rheumatoid arthritis. The results showed numerical differences in disease activity improvement rates between the TAS5315 group and the placebo group at week 12, but the primary endpoint was not achieved. However, TAS5315 demonstrated advantages in disease activity and biomarker improvement, as well as higher risk of bleeding events within 36 weeks. Therefore, a risk-benefit analysis of TAS5315 should be considered.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials

Yoshiya Tanaka, Tsutomu Takeuchi, Derek Haaland, Stephen Hall, Nevsun Inanc, Zhanguo Li, Ricardo M. M. Xavier, Carlos Cara, Nicola Tilt, Peter C. C. Taylor

Summary: This study assessed the efficacy of Certolizumab pegol (CZP) in patients with early and established rheumatoid arthritis (RA) and found that it was effective in reducing symptoms in patients with different rheumatoid factors (RF) levels. CZP may be considered as a treatment option for RA.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Rheumatology

Development of a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs

Fang Song, Hisae Nakatani, Eiji Sugiyama, Shintaro Hirata

Summary: The objective of this study was to develop a nursing practice scale for evaluating the care provided to patients with rheumatoid arthritis receiving biological disease-modifying anti-rheumatic drugs. The results confirmed the reliability, criterion validity, and construct validity of the self-created 19-item nursing practice scale.

MODERN RHEUMATOLOGY (2023)

Article Rheumatology

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

Peter C. Taylor, Michael E. Weinblatt, Iain B. McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O'Shea, Didier Saurigny, Lorrie A. Schifano, Celia Shelton, Julia E. Smith, Millie Wang, Reena Wang, Sarah Watts, Roy M. Fleischmann

Summary: This study investigated the efficacy and safety of otilimab in patients with active rheumatoid arthritis. The results showed that otilimab did not achieve the primary endpoint of ACR20 and did not demonstrate non-inferiority to sarilumab in this patient population.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Effectiveness and safety of rituximab in special types of rheumatoid arthritis

Satoshi Takanashi, Yasushi Kondo, Shuntaro Saito, Jun Kikuchi, Hironari Hanaoka, Tsutomu Takeuchi, Yuko Kaneko

Summary: Rituximab is an effective treatment option for patients with lymphoproliferative disorder and rheumatoid vasculitis, showing significant improvements in disease activity scores and reduction in prednisolone dosage, with a good safety profile.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Pharmacology & Pharmacy

Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis

Tsutomu Takeuchi, Yukihiro Chino, Yoko Mano, Masafumi Kawanishi, Yuri Sato, Saeko Uchida, Yoshiya Tanaka

Summary: A population pharmacokinetic (PK) model was developed to assess the effects of potential PK covariates on the PK of ozoralizumab. The model adequately described the PK of ozoralizumab in Japanese patients with rheumatoid arthritis, and body weight was found to have the greatest impact on its PK.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Rheumatology

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials

Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato, Saeko Uchida, Yoshiya Tanaka

Summary: This study aimed to analyze the pharmacokinetics (PK) of Ozoralizumab (OZR) and its correlation with clinical efficacy in rheumatoid arthritis (RA) patients. The results showed that the maximum plasma concentration (C-max) of OZR was reached in 6 days, with a half-life of 18 days. The exposure of OZR correlated negatively with patient body weight and was not significantly affected by other patient baseline characteristics. The efficacy of OZR was sustained independent of trough concentration when administered subcutaneously at a dose of 30 mg every 4 weeks for 52 weeks.

ARTHRITIS RESEARCH & THERAPY (2023)

Article Immunology

Expression of factor XIII originating from synovial fibroblasts and macrophages induced by interleukin-6 signaling

Hirofumi Watanabe, Sho Mokuda, Tadahiro Tokunaga, Hiroki Kohno, Michinori Ishitoku, Kei Araki, Tomohiro Sugimoto, Yusuke Yoshida, Toshihiro Yamamoto, Mayuko Matsumoto, Junya Masumoto, Shintaro Hirata, Eiji Sugiyama

Summary: This study found that FXIII-A is expressed in M2 macrophages, while FXIII-B is expressed in fibroblast-like synoviocytes. In patients with rheumatoid arthritis, anti-IL-6 receptor antibody treatment leads to decreased FXIII activity. IL-6 promotes the expression of FXIII-A, while the anti-IL-6 receptor antibody inhibits FXIII-A expression. FXIII-B is more abundantly secreted in synoviocytes and it elevates the expression of genes associated with antiapoptotic molecules and chemokines.

INFLAMMATION AND REGENERATION (2023)

Article Rheumatology

Appearance of anti-MDA5 antibody-positive dermatomyositis after COVID-19 vaccination

Tomohiro Sugimoto, Ai Yorishima, Naoya Oka, Sho Masuda, Naoki Nakamoto, Genki Kidoguchi, Hirofumi Watanabe, Yusuke Yoshida, Sho Mokuda, Shintaro Hirata

Summary: This study describes a case of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis developed after COVID-19 vaccination. The patient was also diagnosed with slowly progressive insulin-dependent diabetes positive for anti-glutamic acid decarboxylase antibody. The patient expressed the DRB1*04:05 allele in the human leukocyte antigen test.

MODERN RHEUMATOLOGY CASE REPORTS (2023)

Article Rheumatology

Fluorodeoxyglucose-positron emission tomography/computed tomography-positive ear lesions responsive to immunosuppressive therapy in a patient with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis

Yuki Murao, Yusuke Yoshida, Naoya Oka, Ai Yorishima, Sho Masuda, Tomohiro Sugimoto, Rina Ono, Yutaka Hirokawa, Shintaro Hirata

Summary: This case report presents the clinical manifestations and treatment course of a 74-year-old woman with occult middle ear involvement of ANCA-associated vasculitis (OMAAV), detected by FDG-PET/CT. The FDG-PET/CT showed remarkable uptake in the surrounding areas of the bilateral Eustachian tubes and left middle ear, which was only partially detected on magnetic resonance imaging. The patient's positive response to immunosuppressive therapy suggests that FDG-PET/CT can be helpful in distinguishing OMAAV from other non-inflammatory middle ear diseases and detecting occult treatment-responsive OMAAV lesions.

MODERN RHEUMATOLOGY CASE REPORTS (2023)

No Data Available